Ipsen S.A. EO-Obl. 2025(25/32)

BID
-
ASK
-
0 Nom.0 Nom.
07/22, 07:28:56 AM

SPREAD (ACT/ REL)- / -
CHANGE COMPARED WITH PREVIOUS DAY (PRICE)0.15%
TODAY'S HIGH (PRICE)99.344
TODAY'S LOW (PRICE)99.179
Week 52 High (Price)102.39
Week 52 Low (Price)98.50

Yield Curves

Type of financial instrument

Corporate Bond

Sub-Type

Technology

Yield

4.04

Yield spread Bundesanleihe

1.1617

Tradable for private investors

Minimum amount tradeable unit

100,000.00

Maturity

25/03/2032

Interest Rate

3.875 %

Currency

Euro

Facts & figures

Price data


TRADE PLATFORM	Börse Stuttgart (XSTU)
LAST PRICE / YIELD	99.216 G / 4.04	0 Units
PRICE DETERMINATION TIME	07/21/2026 / 09:45:33 PM
DAILY VOLUME (NOMINAL)	0
YIELD SPREAD	1.1617
FIXINGPRICE	-
DAILY HIGH / LOW	99.344	99.179
PREV. DAY'S PRICE	99.366	(07/20)
CHANGE DAY BEFORE	-0.15	-0.15 %
52 WEEK HIGH / LOW	102.387 (02/24)	98.496 (03/27)

More Price Information

Master Data


WKN	A4D8WE
ISIN	FR001400YD27
SYMBOL	-
EXCHANGE SEGMENT	Freiverkehr
TYPE OF FINANCIAL INSTRUMENT	Corporate Bond
SUB-TYPE	Technology
ISSUER	Ipsen S.A.
S&P RATING	Please log in to view this field
(TRADING) SEGMENT / TICKS	-/ -
TRADING HOURS	07:30:00 AM - 10:00:00 PM
INTEREST RATE	3.875 %
INTEREST RUN FROM	25/03/2025
NEXT INTEREST PAYMENT	25/03/2027
UNIT INTEREST FROM NOMINAL AMMOUNT	1.306 %


TRADING CURRENCY / NOTATION	Euro/ Percent
NOMINAL CURRENCY	Euro
SETTLEMENT CURRENCY	Euro
QUOTATION	Continuous trading
ISSUING VOLUME	500.00 Mil.
MINIMUM AMOUNT TRADEABLE UNIT	100,000.00
SMALLEST TRADEABLE UNIT	100,000.00
MATURITY	25/03/2032
MARKET MAKER	-
STEP UP/ DOWN WHEN RATING CHANGES	No
STEP UP FIXED AT ISSUE	No
STEP DOWN FIXED AT ISSUE	No
BOND CALLABLE BY THE ISSUER	No
BOND IS SUBORDINATED	No

Tradability Information

Please log in to see the tradability information for this stock.

Not registered yet? Create your free account here.

Company profile

Ipsen SA manufactures pharmaceutical products for oncology, neuroscience, and rare diseases. It operates through the following segments: Specialty Care. The Specialty Care segment focuses on oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and rare diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.